Carol Breslauer, as the Managing Principal of Carol Breslauer Consulting, LLC, brings a wealth of expertise and a strategic vision to the clinical research landscape, particularly within the realms of small pharmaceutical and biotech companies. With a robust background in clinical operations and trial project...
Carol Breslauer, as the Managing Principal of Carol Breslauer Consulting, LLC, brings a wealth of expertise and a strategic vision to the clinical research landscape, particularly within the realms of small pharmaceutical and biotech companies. With a robust background in clinical operations and trial project management, Carol excels in providing senior-level independent consulting services that focus on process review and improvement. Her keen insights into clinical monitoring and regulatory submissions enable her to identify inefficiencies and implement effective solutions that enhance operational workflows.
At the heart of Carol’s consulting practice is her commitment to fostering collaboration among cross-functional teams, ensuring that each project aligns with industry standards and best practices. She has successfully led key projects that involve the development and validation of Standard Operating Procedures (SOPs), streamlining processes that are critical for compliance and quality assurance in clinical trials. Her proficiency in software validation and data management, particularly using tools like Microsoft Excel and PowerPoint, allows her to deliver comprehensive training and support to clients, empowering them to leverage technology effectively.
Carol's specialized knowledge in oncology and laboratory medicine further distinguishes her in the field, as she navigates the complexities of clinical development with a focus on innovative therapies. By sharing her insights and experience, she not only enhances the operational capabilities of her clients but also contributes to the advancement of clinical research practices. Her passion for improving processes and her dedication to the success of small pharma and biotech companies make her an invaluable asset in the ever-evolving landscape of clinical research.
